Quick Facts

• Conditions Supported: Severe nausea and vomiting; manifestations of psychotic disorders; short-term management of generalized non-psychotic anxiety.
• Therapeutic Goal: To assist in the control of symptoms associated with these conditions.

Prochlorperazine Actavis is a prescription drug approved for the management of specific conditions in adults. The drug is utilized in the care plan for patients experiencing severe nausea and vomiting. This therapeutic application is typically intended for cases where other forms of support may be insufficient, including situations linked to post-operative recovery or other underlying illnesses.

Additionally, this medication is indicated for the management of the manifestations associated with psychotic disorders, such as schizophrenia. It may also be considered for the short-term treatment of generalized non-psychotic anxiety. The use of this drug for anxiety is generally limited to specific duration and doses, and it is not considered a first-line therapy for most patients with this condition. The drug is an approved therapy for these domains. Treatment decisions, including duration and appropriateness, should always be determined by a healthcare professional.

Eligibility Map: Official Regulatory Information

This section details the official population eligibility and non-eligibility for Prochlorperazine, based strictly on government regulatory documents.

Eligibility-Related Restrictions

Connection to the overall eligibility profile:

Regulatory documents explicitly define the boundaries of use, permitting the medicine for adults and restricting use in children by specific age and weight criteria. The profile mandates that the drug is strictly prohibited for any patient with severe CNS depression, known allergy to the drug class, or critical organ failure. This regulatory framework ensures that population-specific risks are documented and addressed.

Official Interaction Profile

This medication's interaction profile is defined by restrictions on use with central nervous system depressants, specific drug-drug toxicity risks, and known pharmacokinetic changes.

Pharmacokinetic and Functional Interactions

Prochlorperazine is metabolized via the cytochrome P450 system, necessitating monitoring when co-administered with medications that stimulate or inhibit these enzymes. A clinically significant pharmacokinetic interaction occurs with food, as administration with meals slows absorption and results in a documented reduction of Cmax by 23% and AUC by 13% [FDA 3.4].

Additionally, the drug's antiemetic action creates a functional constraint by potentially masking signs of overdosage from other medicines or obscuring the diagnosis of other conditions such as intestinal obstruction or Reye’s syndrome [FDA 1.5]. Caution is advised for its use in specific populations, including elderly patients with dementia-related psychosis, where an increased risk of death has been documented [FDA 1.4].

The structure of this interaction profile highlights mandated prohibitions and significant risk factors established in official regulatory documents.

Prochlorperazine Actavis functions as a multi-target antagonist, modulating signaling within key physiological pathways by acting on three major classes of neurotransmitter receptors central to the processing of sickness and imbalance.

Dopamine Blockade in the Anti-Emetic Cascade

This core domain involves the drug's activity as an antagonist of Dopamine mathbfD2 receptors, primarily situated within the Chemoreceptor Trigger Zone (CTZ) of the brainstem. By blocking these receptors, the drug inhibits the crucial afferent signal from the CTZ to the Vomiting Center, which ultimately interrupts the motor command for the emetic reflex.

Multi-Receptor Modulation of Vestibular Signals

The secondary mechanism involves the antagonism of Histamine mathbfH1 and Muscarinic Cholinergic mathbfM1 receptors found within the brain's pathways that process signals from the Vestibular System (balance organs). This targeted receptor blockade dampens the over-active neural input generated in the Vestibular System pathways, contributing to the modulation of afferent signal processing related to balance and spatial orientation.

Prochlorperazine Actavis is administered via several approved routes, including oral tablets, specialized buccal tablets, rectal suppositories, and sterile solutions for intramuscular (IM) or intravenous (IV) injection.

Administration Routes and Standard Dosing

The dosage regimen is determined by the specific condition being addressed. For severe nausea and vomiting, the oral dose is typically 5 mg to 10 mg taken three or four times daily, with a maximum daily dose generally limited to 40 mg. Acute symptoms may be addressed with an IM injection of 5 mg to 10 mg, repeatable every three to four hours, not exceeding 40 mg per day. IV administration must be a slow injection or infusion at a rate not exceeding 5 mg per minute.

Specific Use Instructions

Buccal tablets are designed for dissolution; they must be placed high against the upper gum and allowed to dissolve completely, and should not be chewed or swallowed whole. Oral tablets may be taken with or without food, but the buccal form is often taken after meals. The use of the oral form for non-psychotic anxiety is restricted to short-term treatment, not exceeding 12 weeks.

Population Dosing Rules

Dosing for older adults is generally initiated at the lower end of the recommended range. Prochlorperazine is not recommended for children under two years of age or weighing less than 9 kg (20 lbs). Pediatric dosing is specifically determined by the child's weight and age, with strict maximum daily limits. If a non-motion sickness dose is missed, the standard instruction is to skip the missed dose and continue the regular schedule; a double dose must never be taken.

Research evidence / Overview of studies for Prochlorperazine Actavis

Evidence for Use in Acute Nausea, Vomiting, and Vertigo

Research in this area has primarily involved short-term Randomized Controlled Trials (RCTs) that compared the medication against an inactive placebo or an agent commonly used in similar research. These studies were structured to monitor and measure the frequency of vomiting and track changes in patient-reported nausea severity scores over brief timeframes. The findings describe patterns observed regarding the proportion of patients who reached a defined end-point for vomiting frequency. Research highlights short-term changes in perceived discomfort measured during the study period. Follow-up durations are limited, meaning long-term outcomes or the management of chronic, persistent conditions are not fully established.

Evidence for Use in Manifestations of Psychotic Disorders

This area presents information from clinical studies and regulatory reviews supporting the initial authorization, which examined patterns in symptom progression in conditions characterized by fluctuating manifestations. Studies explored the relationship between the use of this medication and measured outcomes, often in comparison to other agents, in patients with psychotic disorders. Research has focused on outcomes related to systemic or functional imbalance using standardized rating scales. However, evidence quality varies across studies due to the age of some core trials, and long-term effects for continuous use are not fully established.

Studies in Special Populations and Uncertainties

Research has explored the use of this medication in children, specifically those older than two years of age, in studies examining outcomes linked to nausea and vomiting. Data available for very young children and infants remain insufficient. Studies also examined effects in older adults; however, certainty remains low regarding specific efficacy in elderly populations with certain underlying conditions, meaning results apply only to the populations studied in the original submissions. A key limitation across the entire evidence base is that follow-up durations were limited in many trials, resulting in documented evidence gaps for long-term use and comparative effectiveness against newer treatments.

Key Studies & References Prochlorperazine - DrugBank Online (Mechanism, Pharmacokinetics, Tardive Dyskinesia Risk)

Official Storage and Disposal Requirements

Prochlorperazine Actavis must be stored strictly according to regulatory labeling to maintain stability and safety.

Storage constraints are defined by the need to protect the light-sensitive active ingredient from degradation. The product must be kept out of the reach of children, and disposal must follow established pharmaceutical waste guidelines.